2021

Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay

Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Aug, 2021 Home  >  Resources  >  Press Release  > Pillar Biosciences received premarket approval from FDA for its ONCO/Reveal™ Dx Lung and Colon Cancer Assay Pillar Biosciences announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its ONCO/Reveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors. Please click here for details.

Renovation of molecular diagnostic laboratory in HKSTP finished

Renovation of molecular diagnostic laboratory in HKSTP finished Jul, 2020 Home  >  Resources  >  Press Release  > Renovation of molecular diagnostic laboratory in HKSTP finished Joined Hong Kong Science and Technology (HKSTP) as a Tenant company and started to build a molecular diagnostic laboratory in HKSTP. AMDL started its centralized laboratory in the HKSTP, where it is a hub of talents and innovations in R&D industry in Hong Kong. We hope to encounter more opportunities with the world-class developers here.

Scroll to Top